Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops
Bausch + Lomb announced that Health Canada has approved LUMIFY® (brimonidine tartrate ophthalmic solution 0.025% w/v), the first and only over the counter (OTC) eye drop developed with low-dose brimonidine tartrate to relieve redness of the eye due to minor eye irritations for adults.
“With Health Canada’s approval of LUMIFY®, we are excited to be able to now offer Canadians a new option to help relieve their red, irritated eyes,” said Joe Gordon, president, Global Consumer, Surgical and Vision Care.
LUMIFY® works by selectively targeting redness and thereby reducing the potential for side effects such as rebound redness and tachyphylaxis. In clinical trials, LUMIFY® eye drops demonstrated significant reduction in ocular redness seen as early as one minute and persisted up to eight hours. An in-home-use-study with over 300 participants also resulted in a 95% satisfaction rating for the product.
LUMIFY® is expected to be available at all major pharmacy retailers in Canada by July 2022 in both 3.5 mL and 7.5 mL size formats.
Click HERE for the full press release.